Seeking Alpha News (Wed, 14-Jan 5:19 PM ET)
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Globe Newswire (Wed, 14-Jan 5:17 PM ET)
Market Chameleon (Tue, 23-Dec 6:44 AM ET)
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods IBS Test
Globe Newswire (Tue, 23-Dec 8:19 AM ET)
Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio
Globe Newswire (Thu, 11-Dec 8:08 AM ET)
Globe Newswire (Tue, 25-Nov 8:19 AM ET)
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Globe Newswire (Thu, 6-Nov 8:19 AM ET)
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Biomerica trades on the NASDAQ stock market under the symbol BMRA.
As of January 16, 2026, BMRA stock price declined to $2.57 with 16,467 million shares trading.
BMRA has a beta of 2.23, meaning it tends to be more sensitive to market movements. BMRA has a correlation of 0.14 to the broad based SPY ETF.
BMRA has a market cap of $7.76 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BMRA traded as high as $25.12 and as low as $1.93.
The top ETF exchange traded funds that BMRA belongs to (by Net Assets): VXF.
BMRA has underperformed the market in the last year with a return of -54.5%, while the SPY ETF gained +18.1%. In the last 3 month period, BMRA fell short of the market, returning -14.6%, while SPY returned +5.0%. However, in the most recent 2 weeks BMRA has outperformed the stock market by returning +1.6%, while SPY returned +1.2%.
BMRA support price is $2.54 and resistance is $2.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMRA shares will trade within this expected range on the day.